Harbour BioMed announced the appointment of Dr. Humphrey Gardner as Chief Medical Officer. Dr. Gardner will be responsible for leading the global product development of the Company, including pipeline strategy, clinical development plan and operations, and product registration. Dr. Gardner has more than 30 years industry experience, achievement and leadership in clinical development and translational medicine, including over 20 years of experience in the pharmaceutical industry and over 10 years of experience in academia.

Before joining the Company, he served as the chief medical officer at Silicon Therapeutics and the chief of medical oncology at Evelo Biosciences. He also served critical leadership roles at Novartis, AstraZeneca and Biogen.